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A B S T R A C T
Background
This is an updated version of the Cochrane Review previously published in 2017.
Epilepsy is a chronic and disabling neurological disorder, affecting approximately 1% of the population. Up to 30% of people with epilepsy
have seizures that are resistant to currently available antiepileptic drugs and require treatment with multiple antiepileptic drugs in com-
bination. Felbamate is a second-generation antiepileptic drug that can be used as add-on therapy to standard antiepileptic drugs.
Objectives
To evaluate the efficacy and tolerability of felbamate versus placebo when used as an add-on treatment for people with drug-resistant
focal-onset epilepsy.
Search methods
For the latest update we searched the Cochrane Register of Studies (CRS Web), MEDLINE, ClinicalTrials.gov and the WHO International
Clinical Trials Registry Platform (ICTRP), on 18 December 2018. There were no language or time restrictions. We reviewed the reference
lists of retrieved studies to search for additional reports of relevant studies. We also contacted the manufacturers of felbamate and experts
in the field for information about any unpublished or ongoing studies.
Selection criteria
We searched for randomised placebo-controlled add-on studies of people of any age with drug-resistant focal seizures. The studies could
be double-blind, single-blind or unblinded and could be of parallel-group or cross-over design.
Data collection and analysis
Two review authors independently selected studies for inclusion and extracted information. In the case of disagreements, the third review
author arbitrated. Review authors assessed the following outcomes: 50% or greater reduction in seizure frequency; absolute or percentage
reduction in seizure frequency; treatment withdrawal; adverse effects; quality of life.
Main results
We included four randomised controlled trials, representing a total of 236 participants, in the review. Two trials had parallel-group design,
the third had a two-period cross-over design, and the fourth had a three-period cross-over design. We judged all four studies to be at an
unclear risk of bias overall. Bias arose from the incomplete reporting of methodological details, the incomplete and selective reporting
of outcome data, and from participants having unstable drug regimens during experimental treatment in one trial. Due to significant
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methodological heterogeneity, clinical heterogeneity and differences in outcome measures, it was not possible to perform a meta-analysis
of the extracted data.
Only one study reported the outcome, 50% or greater reduction in seizure frequency, whilst three studies reported percentage reduction
in seizure frequency compared to placebo. One study claimed an average seizure reduction of 35.8% with add-on felbamate while another
study claimed a more modest reduction of 4.2%. Both studies reported that seizure frequency increased with add-on placebo and that
there was a significant difference in seizure reduction between felbamate and placebo (P = 0.0005 and P = 0.018, respectively). The third
study reported a 14% reduction in seizure frequency with add-on felbamate but stated that the difference between treatments was not
significant. There were conflicting results regarding treatment withdrawal. One study reported a higher treatment withdrawal for place-
bo-randomised participants, whereas the other three studies reported higher treatment withdrawal rates for felbamate-randomised par-
ticipants. Notably, the treatment withdrawal rates for felbamate treatment groups across all four studies remained reasonably low (less
than 10%), suggesting that felbamate may be well tolerated. Felbamate-randomised participants most commonly withdrew from treat-
ment due to adverse effects. The adverse effects consistently reported by all four studies were: headache, dizziness and nausea. All three
adverse effects were reported by 23% to 40% of felbamate-treated participants versus 3% to 15% of placebo-treated participants.
We assessed the evidence for all outcomes using GRADE and found it as being very-low certainty, meaning that we have little confidence
in the findings reported. We mainly downgraded evidence for imprecision due to the narrative synthesis conducted and the low number
of events. We stress that the true effect of felbamate could likely be significantly different from that reported in this current review update.
Authors' conclusions
In view of the methodological deficiencies, the limited number of included studies and the differences in outcome measures, we have
found no reliable evidence to support the use of felbamate as an add-on therapy in people with drug-resistant focal-onset epilepsy. A
large-scale, randomised controlled trial conducted over a longer period of time is required to inform clinical practice.
P L A I N   L A N G U A G E   S U M M A R Y
Felbamate used with other antiepileptic drugs for drug-resistant focal epilepsy
Background
Up to 30% of people with epilepsy still suffer epileptic seizures despite trying multiple antiepileptic drugs, whether separately or in com-
bination. These people are described as having drug-resistant epilepsy. Drug-resistance is most common in people with focal epilepsy
(epilepsy that initially begins in one area of the brain, but can progress to affect the whole brain). Felbamate is an antiepileptic drug that
might be effective for people with drug-resistant focal epilepsy when used with other antiepileptic drugs.
Aim of the review
This review investigated whether felbamate is effective and tolerable for people with drug-resistant focal epilepsy, when used with other
antiepileptic drugs (add-on therapy).
Results
After searching the available literature, we found four trials, involving 236 participants, that investigated the use of felbamate in people
with drug-resistant focal epilepsy. We included the four trials in the review.
Although three of the trials reported percentage reduction in seizure frequency, they all reported very different results. One reported a
36% reduction in seizure frequency with felbamate, one reported only a 4% reduction with felbamate, and the other trial reported that
there was no difference between felbamate and placebo (an inactive, dummy drug). We therefore found no clear evidence to suggest that
felbamate was better than placebo at reducing seizure frequency for people with drug-resistant focal epilepsy. Additionally, there was
mixed evidence about whether more people withdraw from treatment with felbamate or placebo. Notably, less than 10% of people in
each trial withdrew from treatment when they were receiving felbamate, suggesting that felbamate may have good tolerability. The side
effects that were reported by all four trials, suggesting that they are the most common, were headache, dizziness, and nausea.
Quality of evidence
It is important to note that the four trials in this review studied a small number of people, over a short period of time (less than 10 weeks).
We are very uncertain about whether the findings of this review are accurate. It is likely that the true effect of felbamate could be very
different to that reported here. More large trials, conducted over a longer period of time are necessary to improve the certainty of the
findings reported by this review.
The evidence is current to 18 December 2018.
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Summary of findings for the main comparison.   Add-on felbamate compared to placebo for drug-resistant focal epilepsy
Add-on felbamate compared to placebo for drug-resistant focal epilepsy
Patient or population: people with drug-resistant focal epilepsy































In the one study that reported this outcome (Binelli 1999), 38%
of participants who were allocated to add-on felbamate had a >
50% reduction in seizures. Of these, 11% had complete cessation















One study reported a percentage reduction in seizure frequency
of 35.8% for participants randomised to felbamate compared to
a percentage increase of 3.3% for those randomised to placebo
(Binelli 1999). Another study (Leppik 1991), reported a less strik-
ing percentage reduction in seizure frequency with add-on fel-
bamate (4.24 ± 55.61%) but a much larger increase in seizure fre-
quency with add-on placebo (−19.14 ± 79.70%). Notably, the di-
rection of effect was the same for both of these studies. The third
study (Theodore 1991), reported that there was no significant dif-











Three of the studies (Bourgeois 1993; Leppik 1991; Theodore
1991), reported a higher treatment withdrawal amongst partici-
pants randomised to felbamate compared to placebo, however,
one study (Binelli 1999), reported a lower treatment withdrawal
rate for participants randomised to felbamate compared to place-
bo (4 vs 8 participants, respectively). The two cross-over studies








































































































































ipants withdrew from treatment during the placebo treatment pe-











Amongst the adverse effects reported, headache and dizziness
were both reported by all four studies whilst diplopia, nausea and
vomiting were each reported by three of the included studies. Two
of the studies (Bourgeois 1993; Leppik 1991), described the inci-
dence of adverse effects for both treatment groups. The number
of participants experiencing individual adverse effects was consis-
tently higher amongst those randomised to felbamate compared









One study (Bourgeois 1993), reported that motor skills and memo-
ry skills, as assessed by a Short Neuropsychological Test, remained
the same or improved following treatment. The study did not,
however, indicate whether there was any difference in outcome
between the add-on felbamate and placebo treatment groups.
CI: confidence interval; RCT: randomised controlled trial
GRADE Working Group grades of evidence
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different.
Low certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.
Very low certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.
1We downgraded evidence once for risk of bias due to a lack of methodological details provided, incomplete outcome data, incomplete reporting of outcomes, and other potential
bias regarding the stability of participants' drug regimen.
2We downgraded evidence once for imprecision due to the narrative synthesis conducted and the absence of an estimated effect size. We downgraded evidence again for impre-
cision because the number of events did not satisfy the optimal information size.
3We downgraded evidence once for inconsistency because the magnitude of effect varied greatly between the three studies that reported this outcome.
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B A C K G R O U N D
This review is an update of a previously published review in the
Cochrane Database of Systematic Reviews (Issue 7, 2017), titled 'Fel-
bamate as an add-on therapy for refractory epilepsy' (Shi 2017).
Description of the condition
Epilepsy is a chronic and disabling neurological disorder, charac-
terised by seizures of various types and frequency. Epilepsy af-
fects approximately 1% of the population (French 1999). Although
up to two-thirds of people with epilepsy will become seizure-free
on a single antiepileptic drug, up to 30% of people are consid-
ered to be drug-resistant and are not seizure-free, despite multi-
ple medications (Granata 2009). Various criteria have been used to
define drug-resistant epilepsy. The consensus definition of drug-
resistant epilepsy proposed by the Task Force of the Internation-
al League Against Epilepsy (ILAE) is now, "failure of adequate trials
of two tolerated and appropriately chosen and used antiepileptic
drug schedules (whether as monotherapies or in combination) to
achieve sustained seizure freedom" (Kwan 2010).
Over the past 15 to 20 years, numerous second-generation
antiepileptic drugs have become available, since standard drugs
(e.g. carbamazepine, phenytoin, valproate) do not control all
seizures in all people. Felbamate, one of these antiepileptic drugs,
is the subject of this review.
Description of the intervention
Felbamate is an antiepileptic drug that can be taken orally. It is
thought to be a broad-spectrum drug that is effective for a number
of seizure types (Pellock 1999). The use of felbamate has been lim-
ited following reports of aplastic anaemia and hepatic failure (Pel-
lock 1999).
How the intervention might work
The exact mechanism of action is unclear. The following possible
mechanisms have been suggested: the inhibition of N-methyl-D-as-
partate (NMDA) receptor-related sodium currents; the potentiation
of ϒ-aminobutyric acid (GABA)-ergic activity; and the inhibition of
voltage-gated sodium channels (Kleckner 1999; Meldrum 1996; Rho
1994).
Why it is important to do this review
Felbamate is marketed in a number of countries as an add-on treat-
ment. A summary of data regarding its efficacy and tolerability from
randomised controlled trials will help inform treatment decisions.
O B J E C T I V E S
To evaluate the efficacy and tolerability of felbamate versus place-
bo when used as an add-on treatment for people with drug-resis-
tant focal-onset epilepsy.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Studies were required to meet all of the following criteria:
1. Randomised controlled trials;
2. Parallel-group or cross-over design;
3. Double-blind, single-blind, or unblinded;
4. Placebo-controlled.
Types of participants
Participants of any age with drug-resistant focal-onset seizures
(simple focal, complex focal or secondarily generalised tonic-clonic
seizures).
Types of interventions
1. The active treatment group received felbamate in addition to
conventional antiepileptic drug treatment.
2. The control group received matching placebo in addition to con-
ventional antiepileptic drug treatment.
Types of outcome measures
Primary outcomes
50% or greater reduction in seizure frequency
We compared the proportion of participants with a 50% or greater
reduction in seizure frequency during the treatment period com-
pared with the pre-randomisation baseline period.
Secondary outcomes
Absolute or percentage reduction in seizure frequency
Absolute reduction in seizure frequency is the seizure frequency
during the baseline period minus the seizure frequency in the treat-
ment period. Percentage reduction in seizure frequency is the ab-
solute reduction in seizure frequency divided by the seizure fre-
quency during the baseline period, all multiplied by 100.
Treatment withdrawal
We used the proportion of participants having treatment with-
drawn during the course of the treatment period as a measure of
'global effectiveness'. The treatment may have been withdrawn
due to adverse effects, lack of efficacy or a combination of both.
Adverse e7ects
We recorded the proportion of participants experiencing the fol-








We chose aplastic anaemia and hepatic failure as they had been
reported as the potential serious adverse effects of felbamate. We
chose the other adverse effects as we considered them to be com-
mon and important adverse effects of all antiepileptic drugs.
We also extracted data regarding the proportion of participants ex-
periencing the most common adverse effects (up to 10 adverse ef-
fects per study) if they were different from those listed above.
Felbamate add-on therapy for drug-resistant focal epilepsy (Review)









Cochrane Database of Systematic Reviews
Quality of life
Since there is lack of consensus on how quality of life should be
measured, we summarised data qualitatively.
Search methods for identification of studies
We ran the search for the original review on 20 May 2010 and ran
subsequent searches on 24 July 2013, 4 Aug 2015, 20 October 2016,
and 18 December 2018.
Electronic searches
For the latest update, we searched the following databases. There
were no language and time restrictions.
1. The Cochrane Register of Studies (CRS Web, 18 December 2018)
using the search strategy outlined in Appendix 1. This includes
the Cochrane Epilepsy Specialized Register and the Cochrane
Central Register of Controlled Trials (CENTRAL).
2. MEDLINE (Ovid, 1946 to December 17, 2018) using the search
strategy outlined in Appendix 2.
3. ClinicalTrials.gov (18 December 2018) using the search strategy
shown in Appendix 3.
4. WHO International Clinical Trials Registry Platform (ICTRP, 18
December 2018) using the search strategy shown in Appendix 4.
Searching other resources
We reviewed the reference lists of retrieved studies to search for ad-
ditional reports of relevant studies.
We contacted the manufacturers of felbamate and experts in the
field for information about any unpublished or ongoing studies.
Data collection and analysis
Selection of studies
For the current review update, two review authors (RB and KMM) in-
dependently assessed studies for inclusion. We resolved disagree-
ments by discussion.
For the previous review updates and the original review, two review
authors (LS and JG) assessed studies for inclusion, whilst a third au-
thor (TW) arbitrated.
Data extraction and management
We extracted the relevant data from the studies supplied by the au-
thors and the manufacturers of felbamate. During the previous re-
view updates, as well as for the original review, two review authors
(LS and JG) extracted the following information from the included
studies whilst a third author (TW) arbitrated.
Methodological/trial design
1. Method of randomisation and concealment of randomisation
2. Method of blinding
3. Duration of baseline period
4. Duration of treatment period
5. Duration of 'wash-out' period in cross-over studies
6. Dose(s) of felbamate tested
7. Description of withdrawals and dropouts
Participant demographic information
1. Total number of participants allocated to each treatment group
2. Age/sex
3. Types of seizure
4. Mean baseline seizure frequency
5. Number of background drugs
Outcomes
We recorded the number of participants experiencing each out-
come (see Types of outcome measures) per randomised group.
Assessment of risk of bias in included studies
For the current update, two review authors (RB and KMM) inde-
pendently assessed the risk of bias of the included studies using
the Cochrane 'Risk of bias' tool, as outlined in the Cochrane Hand-
book for Systematic Reviews of Interventions (Higgins 2017). During
previous review updates, and during the original review, two oth-
er review authors (LS and JG) independently assessed studies for
bias. In total, we assessed the studies across seven 'Risk of bias' do-
mains.
1. Random sequence generation (selection bias)
2. Allocation concealment (selection bias)
3. Blinding of participants and personnel (performance bias)
4. Blinding of outcome assessors (detection bias)
5. Incomplete outcome data (attrition bias)
6. Selective outcome reporting (reporting bias)
7. Other bias
We described supporting information for each of our judgements
for each study. We resolved disagreements by discussion. If dis-
agreements persisted, a third review author (TW) arbitrated.
Measures of treatment e7ect
We planned to express relative treatment effects as risk ratios with
95% confidence intervals for dichotomous data, and mean differ-
ences with 95% confidence intervals for continuous data. We would
have considered a P value of less than or equal to 0.05 as statisti-
cally significant.
Unit of analysis issues
The inclusion of cross-over studies in a meta-analysis introduces
unit of analysis issues. This is because the repeated measures de-
sign, utilised by cross-over studies, means that each participant
contributes data to both/all treatment groups. The statistical meth-
ods of the meta-analysis require that both treatment groups remain
independent of each other, an assumption that is therefore broken
by the inclusion of cross-over studies (Stedman 2011).
If we had performed a meta-analysis, we would have extracted data
from the first treatment period of the included cross-over studies.
Essentially, we would have regarded the first treatment period as a
parallel study, thus preventing data from the same participant be-
ing considered twice, whilst simultaneously avoiding any issues of
carry-over effect. As we did not conduct a meta-analysis, and there-
fore did not require the assumption of independent groups to be
met, and because the first period data was not available from the
study publications, we have included all data in the narrative syn-
thesis.
Felbamate add-on therapy for drug-resistant focal epilepsy (Review)
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Dealing with missing data
We planned to carry out intention-to-treat analysis according to the
treatment allocation, regardless of the final treatment received. We
would have assumed that participants who did not complete fol-
low-up or who had inadequate seizure data were non-responders.
Assessment of heterogeneity
We assessed clinical heterogeneity by comparing the distribu-
tion of important participant factors between included studies
(age, predominant seizure type, duration of epilepsy, number of
antiepileptic drugs taken at time of randomisation). We assessed
methodological heterogeneity by comparing included studies (ran-
domisation, concealment, blinding, losses to follow-up).
Assessment of reporting biases
We planned to assess the reporting bias, according to Chapter 10
of the Cochrane Handbook for Systematic Reviews of Interventions
(Sterne 2017). Specifically, we had planned to assess potential pub-
lication bias using funnel plots had we included more than nine
studies in the review.
Data synthesis
We planned to analyse the data using Review Manager 5.3 (Review
Manager 2014). Unfortunately, due to the nature of the included
studies, we did not feel that it was appropriate to combine the data
into a meta-analysis. Instead, we conducted a narrative synthesis
of the data.
Subgroup analysis and investigation of heterogeneity
We planned subgroup analysis according to age, seizure type, du-
ration of epilepsy, and number of antiepileptic drugs taken at the
time of randomisation. Due to insufficient data included in the re-
view and due to narrative synthesis, these analyses were not pos-
sible.
Sensitivity analysis
We planned to perform sensitivity analyses to investigate the ro-
bustness of the meta-analysis by removing the studies associated
with high risk of bias, or by excluding studies with large effect size.
Although we were unable to conduct the planned sensitivity analy-
ses, we considered these factors when critically analysing the re-
sults of the review during the discussion (see Summary of main re-
sults).
Summarising and interpreting results
We used the GRADE approach, as outlined in the GRADE Handbook
(Schünemann 2013), to interpret findings, and GRADEpro GDT soft-
ware (which imports data from Review Manager 5 software (GRADE-
pro 2015)), to produce a 'Summary of findings' table. We assessed
all of the review outcomes using GRADE and included them in Sum-
mary of findings for the main comparison. We assessed the evi-
dence for each outcome across eight criteria (risk of bias, inconsis-
tency, indirectness, imprecision, publication bias, effect size, pres-
ence of plausible confounding factors, and dose-response gradi-
ent) to determine its certainty.
R E S U L T S
Description of studies
Results of the search
The searches yielded 184 records, of which 150 records remained
after removing 34 duplicates. We assessed that eight records were
potentially eligible for inclusion after title and abstract screening.
Following the screening of the full-text articles of the eight remain-
ing records, we excluded four of these records (Li 1996; Sachdeo
1990; Theodore 1990; Wilder 1991), and listed the reasons for exclu-
sion in Characteristics of excluded studies. We thus judged that the
remaining four records (Binelli 1999; Bourgeois 1993; Leppik 1991;
Theodore 1991), were eligible for inclusion in the review.
See Figure 1 for the study flow selection diagram (Moher 2009).
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Figure 1.   Flow chart of study selection
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Included studies
See Characteristics of included studies.
Four studies met our inclusion criteria, with a total of 236 partici-
pants (Binelli 1999; Bourgeois 1993; Leppik 1991; Theodore 1991).
Although all four studies were randomised, double-blind, place-
bo-controlled trials, they otherwise largely varied in study design.
Two of the studies were parallel-group trials, one was a two-peri-
od cross-over trial, and the other was a three-period cross-over tri-
al. They utilised varying felbamate doses, varying treatment peri-
ods, differing baseline antiepileptic drugs, and differing methodol-
ogy for assessment of efficacy. Participants randomised in the four
studies also had differing seizure frequency during baseline.
Binelli 1999 was a parallel-group trial including an eight-week base-
line period, followed by an undefined titration period where the
dose was gradually increased to the maximum tolerated dose and
was then maintained over an eight-week maintenance phase. Par-
ticipants were required to have at least eight seizures during the
eight-week baseline period. Additionally, participants' concomi-
tant antiepileptic therapy could be made up of no more than two
of the following drugs: carbamazepine, γ-vinyl-GABA, lamotrigine,
gabapentin, and benzodiazepine, however, there was no descrip-
tion of which drugs the felbamate group or the placebo group re-
ceived. No other inclusion criteria and exclusion criteria were men-
tioned in the study. The study included a total of 83 participants
who were randomised to one of two treatment groups, up to 3600
mg/day felbamate or placebo.
Likewise, Bourgeois 1993 was a parallel-group trial, which consist-
ed of a four-week baseline period as well as a four-week treatment
period, inclusive of a three-day titration period. Specifically, par-
ticipants underwent a routine evaluation for epilepsy surgery at
the end of the four-week baseline period. The treatment period im-
mediately followed the surgical evaluation period and consisted of
eight hospital days and 21 outpatient days. The study utilised strict
diagnosis requiring video/electroencephalogram (EEG)-confirmed
focal-onset seizures. The study publication defined both inclusion
and exclusion criteria. To be eligible for inclusion, seizure frequency
could not exceed an average of four complex focal-onset seizures or
feature more than one secondarily generalised seizure per day, dur-
ing the last three days of the surgical evaluation. Moreover, partici-
pants were also required to have a minimum average of one seizure
per day for the last three days of the surgical evaluation period. Par-
ticipants had to be at least 18 years of age and have a body weight
of at least 40 kg. A total of 64 participants were randomised into the
study by Bourgeois 1993. Participants were randomised to receive
either 3600 mg/day felbamate (or their maximum tolerated dose)
or placebo.
Importantly, during the surgical evaluation period, standard
antiepileptic drugs were reduced or discontinued. Throughout the
subsequent hospitalisation period (the first eight days of the treat-
ment period), the participants continued with the same antiepilep-
tic drug regimen present on the last day of the surgical evaluation
period. Once participants entered the second phase of the treat-
ment period (the 21 outpatient days), participants who were on less
than the full baseline dosage of one standard antiepileptic drug(s)
returned to their pre-surgical evaluation dosage of one antiepilep-
tic drug. If participants were instead on a reduced dosage of two
antiepileptic drugs, the dosage of one was restored to its pre-sur-
gical evaluation dose. All participants in the felbamate group were
treated at the maximum dosage. Again, there was no description of
which baseline antiepileptic drugs were being taken, or which par-
ticipants on which antiepileptic drugs were the best responders to
felbamate.
In contrast to the two previous studies, Leppik 1991 was a two-
period cross-over study. The study included an eight-week base-
line period, an eight- to 10-day titration period and 10-week treat-
ment period with an additional three-week wash-out period. Diag-
nosis of epilepsy was based on the observation of at least one ic-
tal event by trained personnel and was supported by EEG. The in-
clusion criteria (participants required to have four or more focal
seizures per month with no more than 20 subsequent seizure-free
days despite stable plasma concentrations of both phenytoin and
carbamazepine) and exclusion criteria (people with medical condi-
tions other than epilepsy, non compliant or unable to accurately
report seizures) were well described. The concomitant antiepilep-
tic drugs were phenytoin and carbamazepine. The trial included a
total of 59 participants who were randomised to receive either add-
on felbamate (up to a maximum dose of 2600 mg/day) or placebo.
Seizure data from the final eight weeks of the first and second treat-
ment periods were used in the efficacy analyses.
Theodore 1991 was also a cross-over study but instead consisted of
three treatment periods. Specifically, there were four treatment se-
quences to which the 30 included participants could be allocated:
felbamate-placebo-felbamate; felbamate-placebo-placebo; place-
bo-felbamate-placebo; placebo-felbamate-felbamate. The treat-
ments were administered across alternating titration and analysis
periods, each lasting two weeks, and were preceded by a three-
week baseline period. During the felbamate treatment periods,
participants were titrated up to a target dose of 3000 mg/day fel-
bamate.The diagnosis of focal epilepsy was based on clinical (the
observation of focal seizures with or without secondary general-
isation), EEG (onset in one cortical region), and imaging (either
focal imaging abnormality or normal scan) criteria. People who
had at least six seizures during the baseline period, with at least
one seizure occurring per individual week, were eligible for inclu-
sion in the trial. The exclusion criteria (acquired by contacting the
first study author) specified that people with treatable causes of
seizures, metastatic tumours except skin cancer, progressive neu-
rological disorders, other serious medical or psychiatric disorders,
or a history of generalised tonic-clonic status epilepticus were to be
excluded from the trial.
Of note, Theodore 1991 also included a stabilisation period, prior to
the baseline period. During this period, participants' antiepileptic
drug regimens were altered or discontinued, such that participants
were only receiving carbamazepine for the duration of the study.
There was no description of mean baseline seizure frequencies. The
mean seizure frequencies during baseline were not reported and
were unavailable through contacting the first author of the study.
Excluded studies
See Characteristics of excluded studies.
All four excluded studies (Li 1996; Sachdeo 1990; Theodore 1990;
Wilder 1991), investigated the long-term use of felbamate but were
not placebo-controlled, and, therefore, did not meet the inclusion
criteria. Notably, two of the studies (Sachdeo 1990; Wilder 1991),
also did not investigate felbamate as an add-on therapy but instead
administered it as a monotherapy. Another of the excluded stud-
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ies (Theodore 1990), was an open-label, long-term extension study,
which we recognised was a continuation of the cross-over trial by
Theodore 1991.
Risk of bias in included studies
See Figure 2 for a graph illustrating the risk of bias across all studies.
See Figure 3 for a summary of the judgements made for each 'Risk
of bias' domain for each individual study.
 
Figure 2.   'Risk of bias' graph: review authors' judgements about each 'Risk of bias' item presented as percentages
across all included studies
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Figure 3.   'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included
study.
 
The 'Risk of bias' judgement for each domain for each study are de-
tailed in the 'Risk of bias' tables, located below the Characteristics
of included studies tables.
Allocation
We awarded two of the included studies, Binelli 1999 and Lep-
pik 1991, unclear risk of selection bias for both random sequence
generation and allocation concealment. The two studies failed to
describe the method used for either randomisation or allocation
concealment. In contrast, we awarded the studies by Bourgeois
1993 and Theodore 1991 low risk of selection bias for both do-
mains. The study by Bourgeois 1993 most likely used a permuted
block randomisation sequence and participants were allocated to
their respective treatment groups by personnel who were separate
from the clinical sites. In Theodore 1991, a National Institutes of
Health (NIH) statistician generated randomisation schedules and
the pharmacy was then responsible for subsequent treatment allo-
cation, rather than study personnel.
Blinding
Binelli 1999 was described as being double-blind, however, the
study publication failed to provide specific details about how the
blinding was achieved. We thus assessed that this study was at
unclear risk of performance and detection bias. In contrast, cor-
respondence with the authors of Bourgeois 1993 confirmed that
participants and study personnel were blinded by using identical
packaging for both treatment groups. Similarly, Leppik 1991 used
matching placebo which would ensure the effective blinding of par-
ticipants and study personnel. The study publication for Leppik
1991 did, however, also state that all study medication was pre-
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pared under the supervision of an unblinded pharmacist. Although
this suggests that the blinding was broken, it is necessary for the
pharmacist to be unblinded to ensure that study kits are correctly
packaged. We therefore agreed that blinding had most likely been
effectively imposed and maintained. Alternatively, Theodore 1991
clarified upon personal correspondence that none of the partici-
pants, physicians, nurses, social workers, or other study personnel
knew what treatment participants were being given, at any time.
We therefore judged these three studies (Bourgeois 1993; Leppik
1991; Theodore 1991), to be at low risk of performance and detec-
tion bias.
Incomplete outcome data
Twelve out of the 83 (14.5%) randomised participants failed to com-
plete the study by Binelli 1999. The study authors did not conduct
an intention-to-treat analysis to compensate for the loss of data.
We therefore judged that the study was at high risk of attrition bias.
In Leppik 1991, three of the 59 (5.1%) randomised participants did
not complete the trial. Theodore 1991 featured a similar attrition
rate with only two of the 30 (6.7%) randomised participants fail-
ing to complete the trial. Again, we included only the participants
who completed the trial in the analysis, thus indicating that inten-
tion-to-treat analysis was not performed. We are, however, uncer-
tain about whether the data from a small proportion participants
would affect the overall conclusions of the trial. As a result, we have
awarded both studies unclear risk of attrition bias, as opposed to
high risk.
Notably, Bourgeois 1993 was the only included study to perform in-
tention-to-treat analysis. In this study, three of the 64 (4.7%) ran-
domised participants failed to complete the trial, however, their
data were incorporated into subsequent statistical analyses. We
thus judged that this study was associated with low risk of attrition
bias.
Selective reporting
Two of the studies (Bourgeois 1993; Leppik 1991), fully reported the
results for all of the outcomes predefined in their respective meth-
ods sections. We thus judged that both studies were at low risk of
reporting bias.
In contrast, the study publication for Binelli 1999 did not describe
any intended outcomes in the methods section. As a result, we
could not determine whether they had reported all intended out-
comes. One of the cross-over studies (Theodore 1991), did report all
outcomes, however, only reported the primary efficacy outcome,
seizure frequency, for the felbamate treatment periods and failed
to disclose seizure frequency during the placebo-control treatment
periods. Moreover, both of these studies (Binelli 1999; Theodore
1991), also failed to provide details of adverse effects that occurred
during treatment with add-on placebo. We consequently assessed
that both studies were at unclear risk of reporting bias.
Other potential sources of bias
We were unable to determine whether there were any other poten-
tial sources of bias associated with the study by Binelli 1999 be-
cause of the poor reporting of the trial and the lack of methodolog-
ical details provided. We thus suspect that there could potentially
be other sources of bias. We consequently awarded the study an
unclear risk of other bias.
We also judged that Bourgeois 1993 was at unclear risk of
other bias. During the surgical evaluation period, participants'
antiepileptic drug regimens were reduced or discontinued. Then,
during the outpatients phase, the dose of one antiepileptic drug,
taken as part of the participants' regimen, was subsequently in-
creased to the dosage they were taking prior to the surgical evalua-
tion. Altering the dosage of concomitant antiepileptic drugs would
likely influence participants' seizure control but could also affect
their responsiveness to the antiepileptic drug being trialled, felba-
mate. As a result, it is not clear whether the result being reported is
due to the intervention or due to the alterations made to the con-
comitant antiepileptic drugs. Most studies require that participants
must be on a stable drug regimen for at least one month prior to the
study, making this study very unusual in design.
We did not detect any other potential sources of bias for the two
remaining studies (Leppik 1991; Theodore 1991). We thus awarded
these two studies low risk of other bias.
E7ects of interventions
See: Summary of findings for the main comparison Add-on fel-
bamate compared to placebo for drug-resistant focal epilepsy
See Summary of findings for the main comparison.
Due to methodological and clinical heterogeneity, it was not possi-
ble to perform a meta-analysis of the study results. We have there-
fore presented a narrative synthesis for our outcome measures:
50% or greater reduction in seizure frequency, absolute or percent-
age reduction in seizure frequency, treatment withdrawal, adverse
effects and quality of life. Futhermore, because the clinical charac-
teristics of the participants in the four included studies were het-
erogeneous, we were also unable to carry out our planned sub-
group analysis.
50% or greater reduction in seizure frequency
Only one study, involving 83 randomised participants, reported the
primary outcome. Binelli 1999 reported that 38% of participants al-
located to felbamate treatment experienced a 50% or greater re-
duction in seizure frequency. Moreover, 11% of these participants
had complete cessation of seizures. The study authors did not,
however, specify the number of placebo-randomised participants
who attained either 50% or greater seizure reduction or complete
cessation of seizures.
Absolute or percentage reduction in seizure frequency
Three of the included studies (Binelli 1999; Leppik 1991; Theodore
1991), consisting of 172 participants, reported this outcome.
Binelli 1999 reported that participants randomised to add-on fel-
bamate, on average, experienced a 35.8% reduction in seizure fre-
quency during the maintenance period. In contrast, participants
randomised to the placebo group experienced a 3.3% average in-
crease in seizure frequency. The study authors did not provide any
information regarding variability (i.e. standard deviation or confi-
dence intervals) but did report that the difference in percentage
seizure reduction was significant (P = 0.0005).
Leppik 1991 reported that the mean seizure frequency during the
final eight weeks of the treatment period for participants ran-
domised to add-on felbamate was 34.4 seizures per eight weeks
compared to a mean seizure frequency of 40.2 seizures per eight
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weeks for those randomised to placebo. Both absolute reduction
(felbamate: 4.95 ± 24.55, placebo: −0.36 ± 27.19, P = 0.046), and per-
centage reduction in seizure frequency (felbamate: 4.24 ± 55.61,
placebo: −19.14 ± 79.70, P = 0.018) were significantly greater with
add-on felbamate than with add-on placebo. Leppik 1991 per-
formed an additional analysis using the data collected across the
10 weeks of each treatment period and reported that this analysis
revealed similar results.
Theodore 1991 reported an average 14% reduction in seizure fre-
quency during treatment with add-on felbamate. Although the
study publication did specifically state that the percentage reduc-
tion in seizure frequency was not significantly different between the
two treatments, felbamate and placebo, they did not provide the
mean percentage change in seizure frequency during the placebo
treatment period. As a result, the study only partially reported the
outcome.
Bourgeois 1993 did not report this outcome.
Treatment withdrawal
All four included studies (Binelli 1999; Bourgeois 1993; Leppik 1991;
Theodore 1991), involving all 236 randomised participants, report-
ed treatment withdrawal. Binelli 1999 reported that four partici-
pants randomised to felbamate withdrew from treatment. In two
cases treatment discontinuation was caused by adverse effects
(diplopia in one case, asthenia and collapse in the other). One par-
ticipant died from the consequences of a seizure, whilst the fourth
withdrew consent. Eight of the participants randomised to add-on
placebo did not complete the study, however, the study authors did
not provide any reasons.
Bourgeois 1993 reported that two participants in the felbamate
group withdrew from treatment due to adverse effects. One partic-
ipant in the placebo group withdrew consent.
Leppik 1991 reported that three participants withdrew from treat-
ment during the felbamate period because of diplopia, nausea and
vomiting, and fever with malaise, respectively. Theodore 1991 re-
ported that two participants leO the study during the felbamate pe-
riod, one owing to seizure exacerbation and the other due to hy-
ponatraemia, which might specifically relate to the use of carba-
mazepine. Notably, no participants withdrew from treatment dur-
ing the placebo period during either study.
Overall, only one of the four included studies (Binelli 1999), report-
ed a higher treatment withdrawal rate amongst participants receiv-
ing placebo. The other three studies all reported a higher treat-
ment withdrawal rate for participants receiving add-on felbamate.
Of note, the treatment withdrawal rate for participants randomised
to felbamate remained below 10% in all four studies. The most
common reason for treatment withdrawal amongst participants re-
ceiving add-on felbamate was due to adverse effects.
Adverse e7ects
All four included studies (Binelli 1999; Bourgeois 1993; Leppik 1991;
Theodore 1991), involving all 236 randomised participants, report-
ed adverse effects.
Binelli 1999 reported 26 adverse effects in the group of participants
treated with felbamate. The adverse effects were central nervous
system events such as headache, dizziness, ataxia, diplopia, con-
fusion, depression, sedation, and paraesthesia, and gastrointesti-
nal tract events such as stomach pain, nausea, vomiting and loss of
appetite. Only 4.9% (2/41) discontinued the treatment due to the
occurrence of adverse effects. In the group of participants treat-
ed with felbamate, significant weight loss occurred (mean reduc-
tion from 72.9 kg to 71.4 kg). In 19.5% (8/41) of participants, the
decrease in weight was between 5 kg to 7 kg. This weight loss was
justifiable in two cases because of gastrointestinal adverse effects.
Of the participants treated with felbamate, 2.4% (1/41) suffered a
modest and transient reduction in the value of leukocytes. There
was no description of adverse effects in the group of participants
treated with placebo.
Bourgeois 1993 reported that the most commonly occurring ad-
verse effect in both treatment groups was headache (40% (12/30)
felbamate and 12% (4/34) placebo). Other commonly occurring ad-
verse effects in the felbamate group were insomnia (37% (11/30)),
nausea (37% (11/30)), dizziness (23% (7/30)), fatigue (20% (6/30)),
constipation (20% (6/30)), anorexia (20% (6/30)), dyspepsia (17%
(5/30)), anxiety (13% (4/30)), and vomiting (13% (4/30)). The most
common adverse effects in the placebo group were dizziness (15%
(5/34)), dyspepsia (9% (3/34)), somnolence (9% (3/34)), insomnia
(6% (2/34)), fatigue (6% (2/34)), anxiety (6% (2/34)), nausea (3%
(1/34)), constipation (3% (1/34)), and vomiting (3% (1/34)). Only
one participant in the felbamate group had a severe adverse ef-
fect: stupor and confusion (3% (1/30)). Two participants in the fel-
bamate group (7% (2/30)) failed to complete the trial due to adverse
effects.
Leppik 1991 reported that the most frequent adverse effects were
in the central nervous system and gastrointestinal tract, of which
headache (36% (21/59) felbamate and 3% (2/59) placebo), dizzi-
ness (36% felbamate (21/59) and 5% (3/59) placebo), diplopia (36%
(21/59) felbamate and 2% (1/59) placebo), blurred vision (22%
(13/59) felbamate and 5% (3/59) placebo), ataxia (32% (19/59) fel-
bamate and 2% (1/59) placebo), nausea (39% (23/59) felbamate
and 7% (4/59) placebo), and vomiting (25% (15/59) felbamate and
3% (2/59) placebo) were noted.
According to Theodore 1991, adverse effects experienced by par-
ticipants included headache (87% (26/30)), nausea (57% (17/30)),
dizziness (50% (15/30)), diplopia (33% (10/30)), vomiting (33%
(10/30)), blurred vision (30% (9/30)), fatigue (17% (5/30)), and poor
balance (10% (3/30)). Notably, the adverse effects listed account
for all participants and do not differentiate between felbamate and
placebo cross-over periods. The study did, however, state that ad-
verse effects were reported more during treatment periods when
felbamate dosage was either steady or was being increased com-
pared to periods of either no felbamate or when felbamate dosage
was being tapered. Only nausea, double vision and blurred vision
were significantly associated with periods during which felbamate
was administered. Importantly, felbamate led to a significant de-
crease in both blood urea nitrogen and white blood count.
Quality of life
Bourgeois 1993 was the only study to describe quality of life. Dur-
ing the four-week outpatient baseline period the study authors ob-
tained each participant's vital signs and administered the Short
Neuropsychological Test. For those who had the Short Neuropsy-
chological Test and completed the treatment period, motor skills
and memory skills remained the same or were improved. The study
did not, however, provide any detailed data for the Short Neuropsy-
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chological Test, or specify whether there was any significant differ-
ence in outcome between the two treatment groups.
D I S C U S S I O N
Summary of main results
Four studies, representing 236 randomised participants, met the
inclusion criteria for this review (Binelli 1999; Bourgeois 1993; Lep-
pik 1991; Theodore 1991). All four studies were randomised, dou-
ble-blind, placebo-controlled trials. Among them, however, two
were parallel-group design trials, one was a two-period cross-over
trial, and the fourth was a three-period cross-over trial.
All four included studies (Binelli 1999; Bourgeois 1993; Leppik 1991;
Theodore 1991), were at unclear risk of bias. The reporting of im-
portant methodological factors, such as the method of randomisa-
tion, allocation concealment, and blinding was poor in Binelli 1999
and Leppik 1991. Additionally, there was also bias related to in-
complete outcome data associated with both of these studies. For
Bourgeois 1993 there was an issue regarding the unstable drug reg-
imens of participants throughout the trial, and for Theodore 1991,
the incomplete outcome data and selective reporting of outcomes,
specifically only for the intervention group, were of concern. Due
to the differences in study methodology, choice of outcomes and
the inadequate reporting of outcome data, it was not possible to
summarise data in a meta-analysis. We, therefore, narratively sum-
marised the data from the studies included in the review.
With regard to efficacy, two studies demonstrated a significant re-
duction in seizure frequency with add-on felbamate compared to
placebo. The size of the effect was, however, notably very differ-
ent between the two studies. Specifically, one study (Leppik 1991),
reported a much smaller effect with considerable inter-participant
variability, as demonstrated by the large standard deviation value.
In contrast, the other study (Binelli 1999), reported a much greater
effect, but failed to disclose any measure of variability. One study
(Theodore 1991), however, described that there was no significant
difference between add-on felbamate and placebo for seizure re-
duction.
Similarly, there were contrasting reports for treatment withdraw-
al. One study (Binelli 1999), reported a higher treatment withdraw-
al rate amongst participants randomised to placebo, whereas the
three other studies (Bourgeois 1993; Leppik 1991; Theodore 1991),
firstly reported fewer treatment withdrawals overall, and secondly,
consistently observed a higher incidence of treatment withdrawal
for participants receiving felbamate. Overall, the treatment with-
drawal rates for felbamate-treated groups across all four included
studies remained below 10%, suggesting that felbamate may be
well tolerated. Headache, dizziness and nausea were the adverse
effects that were consistently reported by all four included studies,
whilst diplopia and vomiting were each reported by three of the
studies. We could not adequately assess the impact of felbamate
on quality of life in the review as only one study (Bourgeois 1993),
partially reported this outcome.
Notably, in both of the analyses that demonstrated conflicting re-
sults (percentage reduction in seizure frequency and treatment
withdrawal), it was Binelli 1999 that contrasted the findings of the
other studies and reported data that massively favoured felbamate
as an efficacious add-on therapy (i.e. a substantial reduction in
seizure frequency and low treatment withdrawal rate). Moreover, it
was also Binelli 1999 that was associated with either unclear or high
risk of bias across all 'Risk of bias' domains. Caution must therefore
be taken when considering the findings of Binelli 1999. Importantly,
if this study were to be excluded from the narrative synthesis, sim-
ilar to when conducting a sensitivity analysis, this review would be
much less encouraging of the use of felbamate as an add-on ther-
apy.
Although the current data suggest that felbamate may possibly re-
duce seizure frequency, we must emphasise that we are very un-
certain about both whether felbamate does demonstrate a thera-
peutic effect, and, furthermore, whether the size of the effect is of
any clinical significance or relevance. Overall, the current data do
not provide convincing evidence to support the use of add-on fel-
bamate in people with drug-resistant focal-onset epilepsy.
Overall completeness and applicability of evidence
Among the included studies, the felbamate doses (target doses
ranged from 2600 mg/day to 3600 mg/day) and the length of the
treatment periods (2 to 10 weeks in duration) were variable, as
summarised in the Characteristics of included studies table. Conse-
quently, we were unable to combine the data into a meta-analysis.
Instead, we were limited to conducting a narrative synthesis with
the data collected. The variability in study quality and the inconsis-
tency of results between studies also had an impact on our ability
to report accurate findings. Using GRADE, we judged the majority of
the included outcomes as being from very low-certainty evidence,
meaning that we have very little confidence that the effect report-
ed is accurate. It also means that it is possible that the true effect
could be substantially different from that reported here.
Of further note, we suspected that all four studies consisted of sole-
ly adult study populations. Binelli 1999 did not state the inclusion
age for participants, however, the mean age of 33.5 years implies
that they studied an adult population. Consequently, any findings
of this review are potentially only applicable to adults with drug-re-
sistant focal epilepsy and cannot inform readers about the effects
of felbamate in children or adolescents. Similarly, we specifically
searched for studies that only included people with drug-resistant
focal epilepsy, opposed to generalised epilepsy or other epilepsy
types. As a result, the review findings cannot be extrapolated to
other seizure types.
Quality of the evidence
Out of the included studies, Binelli 1999 was associated with the
greatest risk of bias. This was largely due to the very poor report-
ing of methodological details. Additionally, the study also featured
a high attrition rate with more 14% of participants withdrawing
from the study overall. The study authors did not conduct an in-
tention-to-treat analysis to compensate for the loss of data from
the withdrawn participants. Leppik 1991 also had missing method-
ological details. For example, they did not describe the methods
used for random sequence generation and allocation concealment.
Separately, one of the remaining studies was associated with other
bias due to alterations made to participants' concomitant drugs at
multiple time points throughout the trial (Bourgeois 1993), whilst
the other study (Theodore 1991), featured incomplete and selective
reporting of outcome data.
As a result of the risk of bias detected across the included studies,
specifically with regard to Binelli 1999 and Leppik 1991, we down-
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graded the evidence for all of the GRADE-assessed outcomes once.
We then downgraded the evidence for all outcomes twice again for
imprecision. It was firstly necessary to downgrade for imprecision
because of the narrative synthesis employed. During a narrative
synthesis, the effect size is subjectively described, whilst, during a
meta-analysis, an estimated effect size is statistically calculated.
The findings reported from a narrative synthesis are therefore au-
tomatically considered to be imprecise. Secondly, we downgraded
for imprecision because of the low number of events. Notably, the
total number of participants, when considering all studies, was 236
participants. The number of events, therefore, could not satisfy the
optimal information size (normally considered to be more than 400
events; Guyatt 2011). We downgraded the evidence once for incon-
sistency for two of the outcomes, absolute or percentage reduction
in seizure frequency and treatment withdrawal, because of dispar-
ity in either the effect size described or the direction of the effect
reported between the studies.
Overall, our GRADE assessment showed that all five outcomes were
derived from very low certainty-evidence. As a result, we have very
little confidence in the accuracy of the review findings that we have
reported. It is important to acknowledge that the true effect of fel-
bamate is likely to be significantly different to that reported in this
review.
Potential biases in the review process
We are not aware of any potential bias within our search strategies.
We do, however, acknowledge that there are potential issues for
bias within our data extraction. For many of the details regarding
methodology, we were forced to rely upon correspondence with
the study authors because they did not provide details in the origi-
nal study publication. This is specifically in reference to Bourgeois
1993 and Theodore 1991. For example, the Bourgeois 1993 corre-
sponding author reported, "I think that randomisation was by per-
muted block, but I do not remember for sure". Although we have
accepted that randomisation was by random permuted blocks, it
is possible that the study author is remembering incorrectly. Con-
sequently, Bourgeois 1993 and Theodore 1991 could potentially be
associated with more risk of bias than we have awarded here, as we
are relying on the ability of study authors to correctly recall details
retrospectively.
Agreements and disagreements with other studies or
reviews
Our review found that adverse effects were more commonly report-
ed during the felbamate period than the placebo period, particu-
larly headache, nausea and dizziness. Whilst the studies in this re-
view reported adverse effects that were largely either mild to mod-
erate in severity, a literature review by Pellock 1999 reported seri-
ous adverse effects, namely aplastic anaemia and hepatic failure.
Neither of these serious adverse effects were reported by any of the
four studies included in this review.
One reason for this might be that these two severe adverse ef-
fects are small-probability events. The likely incidence of felba-
mate-associated aplastic anaemia is 127 per one million people
(Pellock 1999). A total of 18 cases of hepatic failure had been report-
ed in people receiving felbamate (Pellock 1999), the rate of which
was lower than the incidence of aplastic anaemia. Another reason
might be that the duration of the four included trials was not long
enough for the occurrence of the two severe adverse effects (the
longest exposure time in felbamate was 10 weeks in Leppik 1991).
All cases of aplastic anaemia presented after two and a half to six
months of felbamate therapy (Pennell 1995), whilst the mean time
to hepatic failure presentation was 217 days (range 25 to 939 days)
(Pellock 1999). As of 2006, despite approximately 10,000 to 13,000
patients annually being treated with felbamate, only one addition-
al patient had suffered aplastic anaemia since the first reports of
the event in 1993 and 1994 (Pellock 2006). This thus emphasises
that the serious adverse effects reported are exceptionally rare.
Notably, the reports of these serious adverse effects surfaced with-
in a year of felbamate receiving US Food and Drug Administration
(FDA) approval (French 1999). Subsequently, the majority of pa-
tients were discontinued from treatment with felbamate and were
diverted to treatment with other antiepileptic drugs. The fears and
concerns regarding felbamate likely resulted in diminished phar-
maceutical interest in the drug. Hence explaining why we were only
able to identify one clinical trial that investigated the add-on use of
felbamate, conducted after 1994.
Despite the reports of serious adverse effects, a later review by Pel-
lock 2006, stated that felbamate, when used as an add-on thera-
py, offers, "small, but encouraging, improvements in seizure con-
trol" and should still be regarded as a useful add-on for some in-
dividuals with drug-resistant epilepsy. The review (Pellock 2006),
bases this finding on the observations of studies by Leppik 1991 and
Theodore 1991, both of which are included studies in our current
review. Notably, in this review, our narrative synthesis for the out-
come, absolute or percentage reduction in seizure frequency, was
based on data derived from three studies, Binelli 1999, Leppik 1991
and Theodore 1991. Leppik 1991 described a much more modest
percentage reduction for participants receiving felbamate, com-
pared to Binelli 1999 (4.2% versus 35.8%, respectively). Theodore
1991 meanwhile demonstrated that there was no significant differ-
ence in seizure reduction between the two treatment groups, felba-
mate and placebo. Consequently, the results of neither Leppik 1991
nor Theodore 1991 support the statement made by Pellock 2006.
Instead, the findings of our current review suggest that there is not
a clinically relevant reduction in seizure frequency to justify the risk
of serious adverse effects.
A U T H O R S '   C O N C L U S I O N S
Implications for practice
We have not identified any additional studies since the previous up-
date of this review (Shi 2017). The quality of existing data is poor
and, consequently, it is not possible to ascertain whether there is a
treatment effect, or to define the size of any potential treatment ef-
fect. There is currently no convincing evidence to suggest that fel-
bamate, when used as an add-on therapy, reduces seizure frequen-
cy for people with drug-resistant focal epilepsy. The most com-
monly reported adverse effects in the included short-term studies
were headache, nausea and dizziness. None of the studies report-
ed aplastic anaemia or hepatic failure. Evidence for the use of fel-
bamate as an antiepileptic drug remains insufficient.
Implications for research
A large-scale, randomised controlled trial conducted over a longer
period of time (at least one year) is required to inform clinical prac-
tice. The trial should recruit a heterogeneous population with well-
defined seizure and epilepsy types. This will allow the identification
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of patient factors, pathology, seizure types and baseline antiepilep-
tic drugs associated with the greatest benefit or harm. In addition,
research is increasingly being undertaken into epilepsy genetics,
with regard to the factors contributing to drug-resistant epilepsy,
to identify the people in which antiepileptic drugs will achieve the
greatest efficacy. Such investigation should be incorporated into
future research investigating the use of add-on felbamate.
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Characteristics of included studies [ordered by study ID]
 
Methods Randomised, double-blind, placebo-controlled, multicenter study
8-week baseline period, a period of gradual increase of the drug to the maximum tolerated dose, and 8-
week maintenance phase
Participants 83 participants (mean age 33.5 years) were enrolled and randomised, 45 to felbamate and 38 to place-
bo
The average monthly seizure frequency in baseline period:
1. felbamate: 15.3 ± 22.1
2. placebo: 12.3 ± 6.4
41 participants taking felbamate and 30 participants taking placebo completed the maintenance peri-
od.
Interventions Add-on felbamate or placebo
Binelli 1999 
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A period of gradual increase of the drug to the maximum tolerated dose, but not higher than 3600 mg/
d, and then an 8-week maintenance phase
Outcomes 1. Reduction of seizures





Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Comment: no details were provided regarding random sequence generation
Allocation concealment
(selection bias)





Unclear risk Comment: no details were provided regarding blinding
Blinding of outcome as-
sessment (detection bias) 
All outcomes




High risk Comment: 12 participants did not complete the maintenance period. Study
did not use ITT analysis
Selective reporting (re-
porting bias)
Unclear risk Comment: no details were provided regarding intended outcomes
Other bias Unclear risk Comment: lack of methodological details and poor reporting of the trial





Methods Randomised, double-blind, placebo-controlled, parallel-group, multicenter study
4-week baseline period, 4-week treatment period (including 3-day titration period)
Participants 64 participants were randomised (38 male), aged 17-51 years. 30 participants were randomised to fel-
bamate and 34 to placebo.
Mean 4-weekly baseline seizure frequency
1. felbamate group: simple focal seizure = 4.9, complex focal seizure = 14.1, focal-onset seizures with
generalisation = 0.4
2. placebo group: simple focal seizure = 5.9, complex focal seizure = 7.6, focal-onset seizures with gen-
eralisation = 0.3
Bourgeois 1993 
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Number of other AEDs: felbamate group = 3-9; placebo group = 2-9
Interventions Add-on felbamate or placebo
Felbamate was titrated from 1600 mg/d-3600 mg/d over a period of 3 d and maintained on 3600 mg/d
or the maximum tolerated dose, not to exceed 3600 mg/d
Outcomes 1. Mean rank of seizure frequency
2. Time to 4th seizure
3. Adverse effects
Notes Trial sponsored by Carter-Wallace Laboratories, Inc., the manufacturer of felbamate at the time of con-
duct.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "they were randomised to the felbamate or placebo treatment groups"
Comment: we contacted the study author and the reply was as follows, "I think
that randomisation was by permuted block, but I do not remember for sure".
Allocation concealment
(selection bias)
Low risk We contacted the study author and the reply was as follows, "The randomisa-
tion was done at Wallace Laboratories and no one at the clinical sites was in-





Low risk We contacted the study author and the reply was as follows, "Medication (or
placebo) was provided by Wallace Laboratories to the clinical sites in identical
packages. The study was double-blind. The patients as well as the doctors and
nurses did not know whether the treatment was felbamate or placebo."
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Quote: "double blind", "...the doctors and nurses did not know whether the





Low risk Comment: 3/64 randomised participants failed to complete the study. The 3
participants could not be included in the analysis of mean rank of seizure fre-




Low risk Comment: the outcomes mentioned in the methods were reported.
Other bias Unclear risk Comment: participants were not on stable drug regimens for the duration of





Methods Randomised, double-blind, placebo-controlled, multicenter, cross-over study conducted across two
sites (University of Minnesota and University of Virginia Health Services Center)
2 treatment sequences: felbamate-placebo and placebo-felbamate
Leppik 1991 
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8-week baseline period, 8-10-d titration period and 10-week treatment period with 3-week wash-out
period
Participants 59 participants were randomised, aged 18-55 years. 56 participants (32 male) completed the trial. 31
participants were randomised to the felbamate-placebo sequence and 28 to the placebo-felbamate
Mean 8-weekly baseline seizure frequencies of the 56 participants who completed the trial
1. University of Minnesota site: felbamate-placebo group = 43.6 (16 participants), placebo-felbamate
group = 42.8 (15 participants)
2. University of Virginia site: felbamate-placebo group = 28.9 (14 participants), placebo-felbamate group
= 44.0 (11 participants)
Other AEDs were phenytoin and carbamazepine
Simple focal seizures, complex focal seizures, secondary generalised seizures
Interventions Add-on placebo or felbamate
In the initial 8-10-d treatment, the dosage was increased daily to 3000 mg/d. Due to reports of nausea
and vomiting, the maximum dosage was reduced to 2600 mg/d. The mean felbamate dosage was 2300
mg/d.
Outcomes 1. Seizure frequency reduction
2. Seizure frequency percentage reduction
3. Truncated seizure frequency percentage reduction
4. Adverse effects
Notes Trial was funded by a grant from the National Institute of Neurological Disorders and Stroke (NINDs)
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "...randomised ... clinical trial. Table 1 summarizes the baseline charac-
teristics of these 56 patients by center and randomised treatment sequence."









Low risk Quote: "matching PLB [placebo] capsules...All medications were pre-packed
under the supervision of the unblinded pharmacist."
Comment: matching placebo ensures effective blinding. Pharmacists cannot
be blinded to treatment as they are responsible for preparing the study kits. As
long as they are not otherwise involved in the study then this is acceptable.
Blinding of outcome as-
sessment (detection bias) 
All outcomes




Unclear risk Comment: 3 participants did not complete the trial and, subsequently, were
not included in any statistical analyses. ITT was therefore not conducted. We,
however, judge that the inclusion of data from 3 additional participants is un-
likely to influence the findings of the trial.
Leppik 1991  (Continued)
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Selective reporting (re-
porting bias)
Low risk Comment: the outcomes mentioned in the methods were reported










3-week baseline period, treatments were administered over alternating titration and analysis periods,
each lasting 2 weeks (participants were observed in the hospital for the entire trial period).
Participants 30 participants were randomised (10 male), aged 19-50 years.
1. 8 participants were randomised to felbamate-placebo-felbamate sequence
2. 8 participants were randomised to felbamate-placebo-placebo sequence
3. 7 participants were randomised to placebo-felbamate-placebo sequence
4. 7 participants were randomised to placebo-felbamate-felbamate sequence
Simple focal seizures, complex focal seizures, generalised tonic-clonic seizures
Mean baseline seizure frequencies of the participants were unavailable
The other AED was carbamazepine
Interventions Add-on placebo or felbamate
28 participants who completed the study received felbamate dosage of 3000 mg/d. The 2 exceptions
who leO the study received felbamate dosage of 2400 mg/d
Outcomes 1. The number of seizures experienced by each participant during each of the 3 analysis periods
2. Adverse effects
Notes Received support from the National Institute of Neurological Disorders and Stroke (NINDs) nursing ser-
vice, the NIH and Carter-Wallace, Inc. It was not clear from the publication whether this support was fi-
nancial, methodological, or both.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk We contacted the study author and the reply was as follows, "The randomisa-




Low risk We contacted the study author and the reply was as follows, "The randomisa-
tion schedule was generated by the NIH statistician and administered by the
pharmacy."
Theodore 1991 
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Low risk We contacted the study author and the reply was as follows, "None of the
physicians or nurses or patients knew what drug they were being given, felba-
mate or placebo, at any time."
Blinding of outcome as-
sessment (detection bias) 
All outcomes





Unclear risk Quote: "47 individuals were enrolled, 17 were not randomised, 2 of the 30 ran-
domisation leO the study after randomisation."
Comment: the 2 participants were not included in the statistical analyses
therefore ITT was not conducted. However, the inclusion of data from 2 addi-
tional participants is unlikely to influence the findings of the trial.
Selective reporting (re-
porting bias)
Unclear risk Comment: the outcomes mentioned in the methods were reported, however,
the study authors did not report seizure frequency during the placebo treat-
ment period
Other bias Low risk Comment: no other sources of bias detected
Theodore 1991  (Continued)
AED: antiepileptic drug; d: day; ITT: intention-to-treat; NIH: National Institutes of Health
 
Characteristics of excluded studies [ordered by study ID]
 
Study Reason for exclusion
Li 1996 Open-label, add-on study, but not a RCT
Sachdeo 1990 Open-label study, but not a RCT. Felbamate was also used as a monotherapy.
Theodore 1990 Open-label, long-term extension study, but not a RCT.
Wilder 1991 Open-label add-on study, but not a RCT. Felbamate was also used as a monotherapy.
RCT: randomised controlled trial
 
 
A P P E N D I C E S
Appendix 1. Cochrane Register of Studies (CRS Web) search strategy
1. (felba* or taloxa):AB,KW,MC,MH,TI AND CENTRAL:TARGET
2. MESH DESCRIPTOR Epilepsy EXPLODE ALL AND CENTRAL:TARGET
3. MESH DESCRIPTOR Seizures EXPLODE ALL AND CENTRAL:TARGET
4. (epilep* OR seizure* OR convuls*):AB,KW,MC,MH,TI AND CENTRAL:TARGET
5. #2 OR #3 OR #4 AND CENTRAL:TARGET
6. #1 AND #5 AND CENTRAL:TARGET
7. #6 AND >20/10/2016:CRSCREATED
Felbamate add-on therapy for drug-resistant focal epilepsy (Review)
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Appendix 2. MEDLINE search strategy
This strategy was based on the Cochrane highly sensitive search strategy for identifying randomised trials (Lefebvre 2011).
1. felbamate.nm. or (felba* or taloxa or "ADD-03055" or "W-554" or "ADD 03055" or "W 554").tw.
2. exp Epilepsy/
3. exp Seizures/
4. (epilep$ or seizure$ or convuls$).tw.
5. 2 or 3 or 4
6. exp *Pre-Eclampsia/ or exp *Eclampsia/
7. 5 not 6
8. (randomized controlled trial or controlled clinical trial or pragmatic clinical trial).pt. or (randomi?ed or placebo or randomly).ab.
9. clinical trials as topic.sh.
10. trial.ti.
11. 8 or 9 or 10
12. exp animals/ not humans.sh.
13. 11 not 12
14. 1 and 7 and 13
15. (monotherap$ not (adjunct$ or "add-on" or "add on" or adjuvant$ or combination$ or polytherap$)).ti.
16. 14 not 15
17. remove duplicates from 16
18. limit 17 to ed=20161020-20181218
19. 17 not (1$ or 2$).ed.
20. 19 and (2016$ or 2017$ or 2018$).dt.
21. 18 or 20
Appendix 3. ClinicalTrials.gov search strategy
Interventional Studies | Epilepsy | Felbamate | First posted on or after 10/20/2016




Date of registration between 20/10/2016 and 18/12/2018
W H A T ' S   N E W
 
Date Event Description
2 August 2019 Amended Minor copyedits carried out
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H I S T O R Y
Protocol first published: Issue 1, 2010
Review first published: Issue 1, 2011
 
Date Event Description
18 December 2018 New citation required but conclusions
have not changed
The conclusions are unchanged. The term 'partial' has been re-
placed by 'focal', in accordance with the most recent classifica-
tion of epilepsies of the International League Against Epilepsy
(Scheffer 2017).
18 December 2018 New search has been performed Searches updated 18 December 2018; no new studies identified.
20 October 2016 New search has been performed Searches updated 20 October 2016; one new study (Binelli 1999)
has been included.
20 October 2016 New citation required but conclusions
have not changed
The conclusions are unchanged.
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D I F F E R E N C E S   B E T W E E N   P R O T O C O L   A N D   R E V I E W
1. In the protocol, we defined drug-resistant epilepsy as "continued seizures despite antiepileptic drug treatment" (French 2006), and in
the review, we used the definition proposed by the Task Force of the International League Against Epilepsy (ILAE) "failure of adequate
trials of two tolerated and appropriately chosen and used antiepileptic drug schedules (whether as monotherapies or in combination)
to achieve sustained seizure freedom" (Kwan 2010).
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2. In the protocol, we planned to summarise data in a meta-analysis, assess the reporting biases, and do sensitivity analyses. In the review,
due to the clinical and methodological heterogeneity in the four included trials, we summarised data narratively.
3. In the protocol, we did not consider unit of analysis issues. We have therefore amended the methods to describe how we would deal
with unit of analysis issues in this current review update and in future review updates.
4. The term 'partial' has been replaced by 'focal', in accordance with the most recent classification of epilepsies of the International League
Against Epilepsy (Scheffer 2017).
I N D E X   T E R M S
Medical Subject Headings (MeSH)
Anticonvulsants  [adverse eHects]  [*therapeutic use];  Drug Resistance;  Epilepsies, Partial  [*drug therapy];  Felbamate;  Phenylcarbamates
 [adverse eHects]  [*therapeutic use];  Propylene Glycols  [adverse eHects]  [*therapeutic use];  Randomized Controlled Trials as Topic
MeSH check words
Humans
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